To go beyond the limits of disease and disability, CELLTIUM is shaping our future.

​

Built on precision neurotechnology, CELLTIUM is dedicated to developing new therapies for intractable neurological disorders, with a primary focus on Charcot–Marie–Tooth disease type 1A (CMT1A). Through precision therapeutics, we aim to restore impaired neurological function and help patients and their families reclaim everyday life and a renewed sense of purpose.

​

At CELLTIUM, experts in neuroscience, drug development, and engineering work together as a unified, dedicated team. Powered by our proprietary PRECISION™ HTS platform and innovative bioengineering, we strive to discover novel first-in-class therapeutics that can transform the treatment paradigm for rare, intractable neurological diseases.

​

We are deeply grateful to the patients and families, investors, and partners who are joining us on this journey. Together with you, CELLTIUM will establish a new standard for the treatment of neurological disorders.

​

CELLTIUM Inc.

​